Contraception Clinical Trial
Official title:
A Pilot Descriptive Study On The Spermicidal Efficacy Of A Vaginal Gel Containing Or Not Sodium Lauryl Sulfate In Healthy Women And Their Male Partners
Verified date | February 2021 |
Source | Laval University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There is an urgent need to develop non-hormonal innovative preventive measures under the control of women that can prevent unintended pregnancy. Based on our experimental data, the use of a gel formulation containing SLS could represent a potent and safe topical vaginal spermicide. The impact of such a preventive tool on public health will be enormous. After successfully completing supportive Phase I/II safety trials, the next step is a prospective pilot clinical trial to evaluate the safety and effectiveness of our gel formulation as a spermicidal agent and for preventing unintended pregnancy in healthy women.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 4, 2020 |
Est. primary completion date | December 4, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: Woman 1. Healthy woman seeking to space or delay pregnancy aged between 18 and 49 years 2. Sexually active 3. Willing to give written informed consent to participate in the trial 4. Normal physical and gynecological examination 5. Negative urine pregnancy test at screening 6. Willing to engage in planned heterosexual vaginal intercourse with ejaculation inside the vagina 7. Female participant in first phase of the study must be already using and agreeing continuous use of a reliable method of contraception defined as use of hormonal contraception (pill, patch or injection, in accordance with the approved product label) during treatment with the study product and must agree to maintain the contraceptive method for at least 2 weeks after discontinuation of study product if not participating in second phase of the study. If the female participant participates in the second phase of the study, she must stop using the method of contraception during product application and use only the test product provided (vaginal gel-SLS). Man 1. Healthy man aged 18 years and older 2. Sexually active 3. Normal spermogram at inclusion 4. Normal physical examination 5. Willing to give written informed consent to participate in the trial 6. Willing to engage in planned heterosexual vaginal intercourse with ejaculation inside the vagina for post coital test. Exclusion Criteria: Woman 1. Abnormal physical/gynecological examination 2. Pregnant at enrolment 3. Lactating or breastfeeding 4. History of vaginitis during the last 3 months 5. History of using vaginal medications during the last 3 months 6. History of STIs (genital herpes, HIV, gonorrhea, chlamydiasis, syphilis, vulvo-vaginal or cervical HPV) during the last 12 months 7. STIs at time of screening 8. Abnormal laboratory findings with clinical significance 9. Allergy to applicator material (polyethylene), to gel polymer (polyoxyethylene-polyoxypropylene) 10. History of toxic shock syndrome (TSS) 11. Use of other contraceptive methods during the study period other than the ones accepted in the study including intrauterine device (IUD), diaphragm, spermicide, contraceptive ring and fertility awareness methods (first phase of the study, no contraception during the second phase) 12. Post-menopausal (12 months of spontaneous amenorrhea and =40 years of age) or physically incapable of becoming pregnant with documented permanent sterilization or history of infertility without anterior pregnancy. 13. Women seeking for efficient contraception 14. Current enrolment in any other clinical trial involving investigational drug, vaccine or medical device. 15. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol specified assessments. Man 1. Abnormal physical examination 2. Abnormal spermogram 3. Surgical sterilization 4. History of urinary infections during the last 3 months 5. History of STIs (genital herpes, HIV, gonorrhea, chlamydiasis, syphilis, HPV) during the last 12 months 6. STIs at time of screening 7. Abnormal laboratory findings with clinical significance 8. Allergy to gel polymer (polyoxyethylene-polyoxypropylene) 9. Current enrolment in any other clinical trial involving investigational drug, vaccine or medical device. 10. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol specified assessments. |
Country | Name | City | State |
---|---|---|---|
Canada | Michel Bergeron | Quebec |
Lead Sponsor | Collaborator |
---|---|
Laval University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring motility of spermatozoides in vitro in presence of gel or gel-SLS, and in post-coital test after using gel or gel-SLS | First, the motility of spermatozoides (progressive, non-progressive, or non-motile) in vitro in presence of gel, gel-SLS will be measured.
Second, the motility of spermatozoides in post-coital test after single intravaginal application of gel or gel-SLS will be measured in women. |
3-6 months | |
Secondary | Recording pregnancy occurrence after using gel-SLS | Recording pregnancy (no. of pregnant women) after the intravaginal application of the gel-SLS before each sexual intercourse for a period of 3 months. | 3 months | |
Secondary | Recording adverse events (AE) after using gel-SLS | Recording AE (general and genital AE) after the intravaginal application of the gel-SLS before each sexual intercourse for a period of 3 months. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |